A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
KEYNOTE-C93 (GOG-3064/ENGOT-en15)
NCT05173987
 Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent
KEYNOTE-B21 / ENGOT-en11 / GOG-3053
NCT04634877
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
EndomERA
NCT05634499
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
|
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
MK-2870-005 (ENGOT-en23/GOG-3095)
NCT06132958
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
NCT05611931
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Phuong-Nam (Nathalie) Nguyen
514-934-1934 poste 31975
|
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
MK-2870-005 (ENGOT-en23/GOG-3095)
NCT06132958
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
|
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
XPORT-EC-042
NCT05611931
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
|
Josée Tremblay
514-890-8000 poste 30637
|
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
ENC.1
NCT03914612
Recruiting
|
CISSS DE LAVAL
HOPITAL DE LA CITE-DE-LA-SANTE
|
|
Solange Tremblay
450-668-1010 poste 23603
|
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
MK-2870-005 (ENGOT-en23/GOG-3095)
NCT06132958
Recruiting
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
|
Sabrina Côté
418-541-1000 poste 3065
|
A Phase II, Single-Arm Study of Giredestrant in Patients With Grade 1 Endometrial Cancer
EndomERA
NCT05634499
Recruiting
|
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
|
|
Alessandra Figueiredo De Vasconcelos
514-340-8222 poste 26823
|
Groupe d'étude en oncologie du Québec